BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Wang J, Wang J, Xiao Y, Xu B, Li H, Yang L, Hao X, Ma Y. SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China. Virol J 2017;14:62. [PMID: 28335783 DOI: 10.1186/s12985-017-0708-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Fatima T, Mumtaz H, Khan MH, Rasool S, Tayyeb M, Haider MZ, Hussain ST, Shahzad A, Ali S, Hussain T. Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy. Cureus 2020;12:e11565. [PMID: 33364092 DOI: 10.7759/cureus.11565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liu S, Zhang Q, Shao X, Wang W, Zhang C, Jin Z. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol 2017;50:87-94. [PMID: 28644966 DOI: 10.1016/j.intimp.2017.06.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
3 Casey JL, Feld JJ, MacParland SA. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. Cells 2019;8:E317. [PMID: 30959825 DOI: 10.3390/cells8040317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Butt N, Reema S, Ali Khan M, Abbasi A, Butt S, Khoso MM, Akbar A, Haleem F, Mahesar GB, Fahad A, Qureshi T. Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus 2019;11:e4458. [PMID: 31205844 DOI: 10.7759/cureus.4458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Chen JH, Wu PN, Huang SC, Hsu PJ, Hsu JC. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan. Curr Med Res Opin 2021;37:245-52. [PMID: 33251875 DOI: 10.1080/03007995.2020.1857716] [Reference Citation Analysis]
6 Zhou HJ, Cao J, Shi H, Naidoo N, Semba S, Wang P, Fan YF, Zhu SC. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health 2021;9:779215. [DOI: 10.3389/fpubh.2021.779215] [Reference Citation Analysis]
7 Mohammed AQ, Auckle R, Li HL, Xu SL, Liu L, Zhao DD, Che WL. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. Am J Med Sci 2018;355:566-72. [PMID: 29891040 DOI: 10.1016/j.amjms.2018.02.001] [Reference Citation Analysis]